A Phase 3 interventional study of risankizumab and placebo for risankizumab in Ulcerative Colitis (UC), sponsored by AbbVie. Active, not recruiting at 426 sites in 43 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-20.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Colitis, Ulcerative by AbbVie — 6 open to participants now, 13 under way, 5 of them phase 3. Colitis, Ulcerative · AbbVie.
Among the 53 studies in Colitis, Ulcerative by AbbVie, this one is the 4th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2018, is one of 19 in phase 3, reaches primary completion later than 8 of the 12 other live ones, and was the 27th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →6 of the 53 studies in Colitis, Ulcerative by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Canada, Israel and 2 more countries
Ages 18–75
AbbVie · Sites in Japan
Ages 15+
AbbVie · Sites in United States, Belgium, Brazil and 13 more countries
Ages 2–17
AbbVie · Sites in China
Ages 18+
AbbVie · Sites in Germany
Ages 18+
By country, each count listing its studies:
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 16 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 21 · Phase 4 1
First in 2000; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,242 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 156 across the 31 interventional studies, 200 across the 20 observational. Of the 36 that completed or were terminated, 22 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
5 of the studies in Colitis, Ulcerative by AbbVie that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT06838845AbbVieAn Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC) | 2026-12 |
| NCT05496348AbbVieStudy of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis | 2027-08 |
| NCT06257875AbbVieA Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 53 studies in Colitis, Ulcerative by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC.
This study consists of three sub-studies and a Continuous Treatment Extension (CTE): Substudy 1 is a 52-week, randomized, double-blind, placebo-controlled maintenance study; Substudy 2 is 52-week, randomized, exploratory maintenance study; and Substudy 3 is an open-label long-term extension study for participants who completed Substudy 1 or 2, or participants who responded to induction treatment in Study M16-067 with no final endoscopy due to the Covid-19 pandemic or due to the geopolitical conflict in Ukraine and surrounding impacted regions. The CTE is an open-label extension for Substudy 3 completers to ensure continuous treatment with risankizumab until such time that risankizumab becomes commercially available and/or the subject can access treatment locally.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Participants who have completed Study M16-067 and have achieved clinical response as defined in the protocol.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to receive placebo for risankizumab administered by subcutaneous (SC) injection.
Drug: placebo for risankizumab
Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
Drug: risankizumab
Participants randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection.
Drug: risankizumab
Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
Drug: risankizumab
Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
Drug: risankizumab
Participants who completed Sub-study 1 or 2 receive open-label risankizumab in Sub-study 3.
Drug: risankizumab
Participants who complete Sub-study 3 and continue to tolerate and derive benefit from receiving risankizumab, will continue to receive risankizumab based on their assignment during Sub-study 3. Participants completing Sub-study 3 without receiving risankizumab rescue therapy in any sub-study will receive risankizumab Dose 1 administered by subcutaneous (SC) injection.
Drug: risankizumab
Participants who complete Sub-study 3 and continue to tolerate and derive benefit from receiving risankizumab, will continue to receive risankizumab based on their assignment during Sub-study 3. Participants completing Sub-study 3 and received risankizumab rescue therapy in any sub-study will receive risankizumab Dose 2 administered by subcutaneous (SC) injection.
Drug: risankizumab
subcutaneous (SC) injection
Also known as: ABBV-066, BI 655066, SKYRIZI
subcutaneous (SC) injection
Sub-Study 1: Percentage of Participants Achieving Clinical Remission per Adapted Mayo Score
Clinical remission per Adapted Mayo Score.
Time frame: Week 52
Percentage of Participants with Adverse Events (AE)
An Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Time frame: Up to Week 300
Sub-Study 1: Percentage of Participants Achieving Endoscopic Improvement
Endoscopic improvement per endoscopy subscore.
Time frame: Week 52
Sub-Study 1: Percentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement
Percentage of participants achieving histologic-endoscopic mucosal improvement.
Time frame: Week 52
Sub-Study 1: Percentage of Participants Achieving Endoscopic Remission
Endoscopic remission per endoscopy subscore.
Time frame: Week 52
Sub-Study 1: Percentage of Participants with Clinical Remission per Adapted Mayo Score in Participants with no Corticosteroid Use for 90 days
Clinical remission per Adapted Mayo Score.
Time frame: Week 52
Sub-Study 1: Percentage of Participants with Clinical Remission per Adapted Mayo Score in Participants with a Clinical Remission at Week 0
Clinical remission per Adapted Mayo Score.
Time frame: Week 52
Sub-Study 1: Percentage of Participants Achieving No Bowel Urgency
Percentage of participants achieving no bowel urgency.
Time frame: Week 52
Sub-Study 1: Percentage of Participants Achieving No Abdominal Pain
Percentage of participants achieving no abdominal pain.
Time frame: Week 52
Sub-Study 1: Percentage of Participants Achieving Histologic-Endoscopic Mucosal Remission
Percentage of participants achieving histologic-endoscopic mucosal remission per endoscopy subscore.
Time frame: Week 52
Sub-Study 1: Percentage of Participants Achieving Endoscopic Improvement in Participants with Endoscopic Improvement at Week 0
Endoscopic improvement per endoscopy subscore.
Time frame: Week 52
Sub-Study 1: Percentage of Participants Achieving Clinical Response per Adapted Mayo Score
Clinical response per Adapted Mayo Score.
Time frame: Week 52
Sub-Study 1: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
The FACIT-Fatigue is a validated tool that measures an individual's level of fatigue during their usual daily activities over the past week.
Time frame: Week 0 to Week 52
Sub-Study 1: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)
The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease.
Time frame: Baseline (Week 0) to Week 52
Sub-Study 1: Percentage of Participants Achieving No Nocturnal Bowel Movements
Percentage of participants achieving no nocturnal bowel movements.
Time frame: Week 52
Sub-Study 1: Percentage of Participants Achieving No Tenesmus
Percentage of participants achieving no tenesmus.
Time frame: Week 52
Sub-Study 1: Change in Number of Fecal Incontinence Episodes per Week
Change in number of fecal incontinence episodes per week.
Time frame: Baseline (Week 0) to Week 52
Sub-Study 1: Change in Number of Days per Week with Sleep Interrupted due to UC Symptoms
Change in number of days per week with sleep interrupted due to UC symptoms.
Time frame: Baseline (Week 0) to Week 52
Sub-Study 1: Percentage of Participants with Exposure Adjusted Occurrence of Ulcerative Colitis (UC) Related Hospitalization
Participants with an exposure adjusted occurrence of UC event that results in admission to the hospital.
Time frame: Through Week 52
Showing the first 100 of 426 sites across 43 countries. Choose a country and city above to see the rest.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Started Aug 2018 (actual). Primary completion is estimated for Sep 2028, 121 months after the start.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's planned 121 months is above that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risankizumab